Increase of cannabinoid CB1 receptor density in the hippocampus of streptozotocin-induced diabetic rats

Experimental Neurology

Volumn 204, Issue 1, 2007, Pages 479-484

  Duarte, João M N ^a,b   Nogueira, Célia ^c   Mackie, Ken ^d   Oliveira, Catarina R ^a   Cunha, Rodrigo A ^a,b   Köfalvi, Attila ^a,e  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; MESSENGER RNA; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CONTROLLED STUDY; HIPPOCAMPUS; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NERVE ENDING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; RECEPTOR DENSITY; STREPTOZOCIN DIABETES; ANIMAL; EXPERIMENTAL DIABETES MELLITUS; GENETICS; MEMBRANE; METABOLISM; WISTAR RAT;

ANIMALS; BINDING SITES; DIABETES MELLITUS, EXPERIMENTAL; HIPPOCAMPUS; MALE; MEMBRANES; NERVE ENDINGS; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; RNA, MESSENGER;

EID: 33847311708     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2006.11.013     Document Type: Article

References (36)

1. Ates O., Yucel N., Cayli S.R., Altinoz E., Yologlu S., Kocak A., Cakir C.O., and Turkoz Y. Neuroprotective effect of etomidate in the central nervous system of streptozotocin-induced diabetic rats. Neurochem. Res. 31 (2006) 777-783
2. Berghuis P., Dobszay M.B., Wang X., Spano S., Ledda F., Sousa K.M., Schulte G., Ernfors P., Mackie K., Paratcha G., Hurd Y.L., and Harkány T. Endocannabinoids regulate interneuron migration and morphogenesis by transactivating the TrkB receptor. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 19115-19120
3. Carlson G., Wang Y., and Alger B.E. Endocannabinoids facilitate the induction of LTP in the hippocampus. Nat. Neurosci. 5 (2002) 723-724
4. Chabot C., Massicotte G., Milot M., Trudeau F., and Gagne J. Impaired modulation of AMPA receptors by calcium-dependent processes in streptozotocin-induced diabetic rats. Brain Res. 768 (1997) 249-256
5. Chen, S., Atkins, C.M., Liu, C.L., Alonso, O.F., Dietrich, W.D., Hu, B.R., in press. Alterations in mammalian target of rapamycin signaling pathways after traumatic brain injury. J. Cereb. Blood Flow Metab. (Electronic publication ahead of print).
6. Clodfelder-Miller B., De Sarno P., Zmijewska A.A., Song L., and Jope R.S. Physiological and pathological changes in glucose regulate brain Akt and glycogen synthase kinase-3. J. Biol. Chem. 280 (2005) 39723-39731
7. Cota D., Marsicano G., Tschop M., Grubler Y., Flachskamm C., Schubert M., Auer D., Yassouridis A., Thone-Reineke C., Ortmann S., Tomassoni F., Cervino C., Nisoli E., Linthorst A.C., Pasquali R., Lutz B., Stalla G.K., and Pagotto U. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. 112 (2003) 423-431
8. 1 receptor antagonism increases hippocampal acetylcholine release: site and mechanism of action. Mol. Pharmacol. 70 (2006) 1236-1245
9. 2A receptor density in the hippocampus of streptozotocin-induced diabetic rats. Neurochem. Int. 48 (2006) 144-150
10. 14C]deoxyglucose study. Brain Res. 962 (2003) 169-179
11. Freund T.F., Katona I., and Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 83 (2003) 1017-1066
12. Gai W., Schott-Ohly P., Schulte im Walde S., and Gleichmann H. Differential target molecules for toxicity induced by streptozotocin and alloxan in pancreatic islets of mice in vitro. Exp. Clin. Endocrinol. Diabetes 112 (2004) 29-37
13. Gelfand E.V., and Cannon C.P. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J. Am. Coll. Cardiol. 47 (2006) 1919-1926
14. Gómez del Pulgar T., De Ceballos M.L., Guzmán M., and Velasco G. Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. J. Biol. Chem. 277 (2002) 36527-36533
15. Grillo C.A., Piroli G.G., Wood G.E., Reznikov L.R., McEwen B.S., and Reagan L.P. Immunocytochemical analysis of synaptic proteins provides new insights into diabetes-mediated plasticity in the rat hippocampus. Neuroscience 136 (2005) 477-486
16. Guzmán M., Sánchez C., and Galve-Roperh I. Control of the cell survival/death decision by cannabinoids. J. Mol. Med. 78 (2001) 613-625
17. Hampson R.E., and Deadwyler S.A. Cannabinoids, hippocampal function and memory. Life Sci. 65 (1999) 715-723
18. Hansson A.C., Bermúdez-Silva F.J., Malinen H., Hyytia P., Sanchez-Vera I., Rimondini R., Rodriguez de Fonseca F., Kunos G., Sommer W.H., and Heilig M. Genetic impairment of frontocortical endocannabinoid degradation and high alcohol preference. Neuropsychopharmacology 32 (2007) 117-126
19. Jackson-Guilford J., Leander J.D., and Nisenbaum L.K. The effect of streptozotocin-induced diabetes on cell proliferation in the rat dentate gyrus. Neurosci. Lett. 293 (2000) 91-94
20. Jiang W., Zhang Y., Xiao L., Van Cleemput J., Ji S.P., Bai G., and Zhang X. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J. Clin. Invest. 115 (2005) 3104-3116
21. 2+ signals and insulin secretion in pancreatic beta-cell. Cell Calcium 39 (2006) 155-162
22. Kalkman H.O. The role of the phosphatidylinositide 3-kinase-protein kinase B pathway in schizophrenia. Pharmacol. Ther. 110 (2006) 117-134
23. 1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J. Neurosci. 19 (1999) 4544-4558
24. Katona I., Sperlágh B., Maglóczky Z., Sántha E., Köfalvi A., Czirják S., Mackie K., Vizi E.S., and Freund T.F. GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. Neuroscience 100 (2000) 797-804
25. 1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum. J. Neurosci. 26 (2006) 2991-3001
26. Köfalvi A., Rodrigues R.J., Ledent C., Mackie K., Vizi E.S., Cunha R.A., and Sperlágh B. Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. J. Neurosci. 25 (2005) 2874-2884
27. 1 receptor knockout mice. Science 283 (1999) 401-404
28. Li Z.G., Zhang W., Grunberger G., and Sima A.A.F. Hippocampal neuronal apoptosis in type 1 diabetes. Brain Res. 946 (2002) 221-231
29. Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb. Exp. Pharmacol. 168 (2005) 299-325
30. Matias I., Gonthier M.P., Orlando P., Martiadis V., De Petrocellis L., Cervino C., Petrosino S., Hoareau L., Festy F., Pasquali R., Roche R., Maj M., Pagotto U., Monteleone P., and Di Marzo V. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J. Clin. Endocrinol. Metab. 91 (2006) 3171-3180
31. Peinnequin A., Mouret C., Birot O., Alonso A., Mathieu J., Clarencon D., Agay D., Chancerelle Y., and Multon E. Rat pro-inflammatory cytokine and cytokine related mRNA quantification by real-time polymerase chain reaction using SYBR green. BMC Immunol. 5 3 (2004)
32. Pontieri F.E., Conti G., Zocchi A., Fieschi C., and Orzi F. Metabolic mapping of the effects of WIN 55212-2 intravenous administration in the rat. Neuropsychopharmacology 21 (1999) 773-776
33. Thomas B.F., Gilliam A.F., Burch D.F., Roche M.J., and Seltzman H.H. Comparative receptor binding analyses of cannabinoid agonists and antagonists. J. Pharmacol. Exp. Ther. 285 (1998) 285-292
34. 1. Neuropharmacology 49 (2005) 660-668
35. Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol. Res. 50 (2001) 537-546
36. Trudeau F., Gagnon S., and Massicotte G. Hippocampal synaptic plasticity and glutamate receptor regulation: influences of diabetes mellitus. Eur. J. Pharmacol. 490 (2004) 177-186